Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0000899243-21-035843)

Filing Details

Accession Number:
0000899243-21-035843
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-14 17:30:29
Reporting Period:
2021-09-10
Accepted Time:
2021-09-14 17:30:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1098972 Agenus Inc AGEN Biological Products, (No Disgnostic Substances) (2836) 061562417
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1288123 M Christine Klaskin C/O Agenus Inc.
3 Forbes Road
Lexington MA 02421		 Pfo & Pao No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-09-10 16,563 $3.36 104,176 No 4 M Direct
Common Stock Disposition 2021-09-10 11,120 $6.50 93,056 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option, right to buy Disposition 2021-09-10 16,563 $0.00 16,563 $3.36
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2011-12-14 2021-09-14 No 4 M Direct
Footnotes
  1. The options subject to the transaction reported on this Form 4 would have expired on September 14, 2021.
  2. The number of shares beneficially owned by the reporting person does not reflect 998 shares that were incorrectly reported on prior Form 4s.
  3. Represents sales of shares, as a consequence of the exercise of options, to cover Federal, state and local tax withholding requirements and the exercise price payment related to the option exercise. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.47 to $6.52. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.